This is a binary negative catalyst for a micro-cap issuer that relied on the Bayer collaboration for credibility and potential future revenue. Expect significant downside pressure. The filing does not mention any termination payment or new strategic direction — watch for follow-up disclosure on cash runway and whether AgPlenus can independently monetize the returned assets.
Price Chart
Executive Summary
Evogene subsidiary AgPlenus and Bayer have discontinued their herbicide development collaboration after the target protein failed to meet product criteria. All licensed assets, including the APTH1 protein target, revert to AgPlenus. This is a significant pipeline setback for Evogene, removing a key partnership-driven catalyst and casting doubt on near-term monetization of its ag-tech platform.
Key Facts
- AgPlenus and Bayer discontinued herbicide project on May 18, 2026
- Target protein did not meet required product criteria
- All assets licensed to Bayer (APTH1 protein target and active molecules) revert to AgPlenus
- No financial terms, milestones, or termination payments disclosed in the filing
- Evogene has a market cap of ~$7M, making this a company-defining event
Financial Impact
Undisclosed; the filing states no financial terms. Given the $7M market cap, loss of a major partnered program with Bayer is a material setback that eliminates potential future milestone and royalty cash flows.
Risk Factors
- Complete loss of a major partnered program with no disclosed compensation or new funding
- Evogene's ability to continue as a going concern may be questioned given the combined negative impact of limited cash, no near-term catalyst, and sub-$10M market cap
- Potential Nasdaq delisting risk if market cap or bid price thresholds are breached
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-002773 |
| Document: 0001178913-26-002773-index-headers.html | 0001178913-26-002773 |
| Document: 0001178913-26-002773-index.html | 0001178913-26-002773 |
| Document: 0001178913-26-002773.txt | 0001178913-26-002773 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 3 | $0.3641 | awaiting T+60 | — | $0.3700 (+1.62%) |
Oct 6, 2026 20d ago | SC 13D/A | $0.4106 | awaiting T+60 | — | $0.3700 (−9.89%) |
Oct 6, 2026 20d ago | 6-K | $0.4106 | awaiting T+60 | — | $0.3700 (−9.89%) |
Sep 30, 2026 26d ago | 6-K | $0.4000 | awaiting T+60 | — | $0.3700 (+7.50%) |
Sep 30, 2026 27d ago | EFFECT | $0.4000 | awaiting T+60 | — | $0.3700 (+7.50%) |
Sep 4, 2026 7w ago | 6-K | $0.5379 | awaiting T+60 | — | $0.3700 (−31.21%) |
Aug 18, 2026 9w ago | 6-K | $0.5826 | awaiting T+60 | — | $0.3700 (−36.49%) |
Aug 14, 2026 10w ago | Press Release | $0.6008 | awaiting T+60 | — | $0.3700 (−38.42%) |
Jul 31, 2026 12w ago | 6-K | $0.5400 | awaiting T+60 | — | $0.3700 (−31.48%) |
Jun 16, 2026 18w ago | 6-K | $0.5600 $0.4806 | ▼ −14.18% | ▼ −15.18% | $0.3700 (−33.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers